171 related articles for article (PubMed ID: 21207425)
81. Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.
Shiota M; Bishop JL; Takeuchi A; Nip KM; Cordonnier T; Beraldi E; Kuruma H; Gleave ME; Zoubeidi A
Oncotarget; 2015 Apr; 6(11):9086-98. PubMed ID: 25871401
[TBL] [Abstract][Full Text] [Related]
82. miR-124 Regulates the Epithelial-Restricted with Serine Box/Epidermal Growth Factor Receptor Signaling Axis in Head and Neck Squamous Cell Carcinoma.
Zhang M; Piao L; Datta J; Lang JC; Xie X; Teknos TN; Mapp AK; Pan Q
Mol Cancer Ther; 2015 Oct; 14(10):2313-20. PubMed ID: 26227488
[TBL] [Abstract][Full Text] [Related]
83. A multi-kinase inhibitor APG-2449 enhances the antitumor effect of ibrutinib in esophageal squamous cell carcinoma via EGFR/FAK pathway inhibition.
Luo QY; Zhou SN; Pan WT; Sun J; Yang LQ; Zhang L; Qiu MZ; Yang DJ
Biochem Pharmacol; 2021 Jan; 183():114318. PubMed ID: 33159967
[TBL] [Abstract][Full Text] [Related]
84. Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel.
Ashraf SQ; Nicholls AM; Wilding JL; Ntouroupi TG; Mortensen NJ; Bodmer WF
Proc Natl Acad Sci U S A; 2012 Dec; 109(51):21046-51. PubMed ID: 23213241
[TBL] [Abstract][Full Text] [Related]
85. Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.
Vazquez-Martin A; Oliveras-Ferraros C; Colomer R; Brunet J; Menendez JA
Ann Oncol; 2008 Jun; 19(6):1097-109. PubMed ID: 18283037
[TBL] [Abstract][Full Text] [Related]
86. Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program.
Gorlick R; Kolb EA; Houghton PJ; Morton CL; Phelps D; Schaiquevich P; Stewart C; Keir ST; Lock R; Carol H; Reynolds CP; Maris JM; Wu J; Smith MA
Pediatr Blood Cancer; 2009 Oct; 53(4):594-8. PubMed ID: 19554571
[TBL] [Abstract][Full Text] [Related]
87. Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer.
Harada Y; Sato A; Nakamura H; Kai K; Kitamura S; Nakamura T; Kurihara Y; Ikeda S; Sueoka E; Kimura S; Sueoka-Aragane N
BMC Cancer; 2023 Jan; 23(1):77. PubMed ID: 36690964
[TBL] [Abstract][Full Text] [Related]
88. An EGFR/HER2-Bispecific and enediyne-energized fusion protein shows high efficacy against esophageal cancer.
Guo XF; Zhu XF; Yang WC; Zhang SH; Zhen YS
PLoS One; 2014; 9(3):e92986. PubMed ID: 24664246
[TBL] [Abstract][Full Text] [Related]
89. Structure-activity relationships of novel quinazoline derivatives with high selectivity for HER2 over EGFR.
Lee JW; Choi C; Kim J; Lee S; Kim J; Lee Y; Min KH
Arch Pharm Res; 2022 Mar; 45(3):123-141. PubMed ID: 35314953
[TBL] [Abstract][Full Text] [Related]
90. Gene expression changes as markers of early lapatinib response in a panel of breast cancer cell lines.
O'Neill F; Madden SF; Aherne ST; Clynes M; Crown J; Doolan P; O'Connor R
Mol Cancer; 2012 Jun; 11():41. PubMed ID: 22709873
[TBL] [Abstract][Full Text] [Related]
91. Combined Wee1 and EGFR inhibition reveals synergistic antitumor effect in esophageal squamous cell carcinoma.
Chen D; Hong R; Cao Y; Wu Q; Wang Y; Chen J; Li J; Zhang W; Zhan Q
Carcinogenesis; 2023 Aug; 44(6):451-462. PubMed ID: 37279554
[TBL] [Abstract][Full Text] [Related]
92. Anti-tumour effects of lapatinib on HER2-positive canine prostatic carcinoma cell lines.
Kaji K; Motegi T; Yonezawa T; Momoi Y; Maeda S
Open Vet J; 2024 May; 14(5):1259-1268. PubMed ID: 38938437
[TBL] [Abstract][Full Text] [Related]
93. Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor.
Liao HJ; Carpenter G
Cancer Res; 2009 Aug; 69(15):6179-83. PubMed ID: 19602593
[TBL] [Abstract][Full Text] [Related]
94. Human Blood Serum Counteracts EGFR/HER2-Targeted Drug Lapatinib Impact on Squamous Carcinoma SK-BR-3 Cell Growth and Gene Expression.
Shaban N; Raevskiy M; Zakharova G; Shipunova V; Deyev S; Suntsova M; Sorokin M; Buzdin A; Kamashev D
Biochemistry (Mosc); 2024 Mar; 89(3):487-506. PubMed ID: 38648768
[TBL] [Abstract][Full Text] [Related]
95. Western Blot Analysis of Lapatinib-Mediated Inhibition of the Epidermal Growth Factor Receptor 2 (HER2) Pathway in Breast Cancer Cells.
Wiede LL; Drover S
Methods Mol Biol; 2022; 2508():183-195. PubMed ID: 35737241
[TBL] [Abstract][Full Text] [Related]
96. HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer.
Boulbes DR; Arold ST; Chauhan GB; Blachno KV; Deng N; Chang WC; Jin Q; Huang TH; Hsu JM; Brady SW; Bartholomeusz C; Ladbury JE; Stone S; Yu D; Hung MC; Esteva FJ
Mol Oncol; 2015 Mar; 9(3):586-600. PubMed ID: 25435280
[TBL] [Abstract][Full Text] [Related]
97. Synthesis and biological evaluation of new series of quinazoline derivatives as EGFR/HER2 dual-target inhibitors.
Jiao X; Zhang Q; Zhang Y; Shao J; Ding L; Tang C; Feng B
Bioorg Med Chem Lett; 2022 Jul; 67():128703. PubMed ID: 35364239
[TBL] [Abstract][Full Text] [Related]
98. Discovery and evaluation of cytisine N-isoflavones as novel EGFR/HER2 dual inhibitors.
Wang Y; Yin X; Chen L; Yin Z; Zuo Z
Bioorg Chem; 2022 Oct; 127():105868. PubMed ID: 35816874
[TBL] [Abstract][Full Text] [Related]
99. Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer.
Havaleshko DM; Smith SC; Cho H; Cheon S; Owens CR; Lee JK; Liotta LA; Espina V; Wulfkuhle JD; Petricoin EF; Theodorescu D
Neoplasia; 2009 Nov; 11(11):1185-93. PubMed ID: 19881954
[TBL] [Abstract][Full Text] [Related]
100. Recombinant humanised anti-HER2/neu antibody (Herceptin) induces cellular death of glioblastomas.
Mineo JF; Bordron A; Quintin-Roué I; Loisel S; Ster KL; Buhé V; Lagarde N; Berthou C
Br J Cancer; 2004 Sep; 91(6):1195-9. PubMed ID: 15328518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
